Your browser doesn't support javascript.
loading
Targeted Proteomic Profiling of Cardiogenic Shock in the Cardiac Intensive Care Unit.
Patel, Siddharth M; Lopes, Mathew S; Morrow, David A; Bellavia, Andrea; Bhatt, Ankeet S; Butler, Kayleigh K; D'Antonio, Jessica; Dunn, Michael; Fagundes, Antonio A; Jarolim, Petr; Marin, Ethan P; Morton, Lori; Olenchock, Benjamin O; Senman, Balimkiz; da Silva, Danuzia S; Varshney, Anubodh S; Bohula, Erin A; Berg, David D.
Afiliação
  • Patel SM; Levine Cardiac Intensive Care Unit, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Lopes MS; Levine Cardiac Intensive Care Unit, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Morrow DA; Levine Cardiac Intensive Care Unit, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Bellavia A; Levine Cardiac Intensive Care Unit, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Bhatt AS; Kaiser Permanente San Francisco Medical Center and Division of Research, San Francisco, CA.
  • Butler KK; Levine Cardiac Intensive Care Unit, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • D'Antonio J; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Dunn M; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Fagundes AA; IDOR, D'Or Institute for Research and Education, DFStar Hospital, Brasília, DF, Brazil.
  • Jarolim P; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
  • Marin EP; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Morton L; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Olenchock BO; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Senman B; Duke University School of Medicine, Durham, NC.
  • da Silva DS; University of Minnesota Medical School, Minneapolis, MN.
  • Varshney AS; Division of Cardiovascular Medicine, Department of Medicine, Stanford University, Palo Alto, CA.
  • Bohula EA; Levine Cardiac Intensive Care Unit, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Berg DD; Levine Cardiac Intensive Care Unit, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Article em En | MEDLINE | ID: mdl-38815149
ABSTRACT

BACKGROUND:

We sought to characterize circulating protein biomarkers associated with cardiogenic shock (CS) using highly multiplex proteomic profiling.

METHODS:

This analysis employed a cross-sectional case-control study design using a biorepository of patients admitted to a cardiac intensive care unit between 2017-2020. Cases were patients adjudicated to have CS and controls were those presenting for cardiac critical care without shock, including subsets of patients with isolated hypotension or heart failure (HF). The Olink platform was used to analyze 359 biomarkers with Bonferroni correction.

RESULTS:

The analysis included 239 patients presenting for cardiac critical care (69 cases with CS, 170 non-shock controls). A total of 63 biomarkers (17.7%) were significantly associated with CS after Bonferroni correction compared with all controls. Of these, nine biomarkers remained significantly associated with CS when separately cross-validated in subsets of controls presenting with isolated hypotension and HF cathepsin D, fibroblast growth factor (FGF)-21 and -23, growth differentiation factor (GDF)-15, insulin-like growth factor binding protein-1, N-terminal pro-B-type natriuretic peptide, osteopontin, oncostatin-M-specific receptor subunit beta (OSMR), and soluble ST2 protein (sST2). Four biomarkers were identified as providing complementary information for CS diagnosis with development of a multi-marker model sST2, FGF-23, CTSD, and GDF-15.

CONCLUSION:

In this pilot study of targeted proteomic profiling in CS, we identified nine biomarkers significantly associated with CS when cross-validated against non-shock controls including those with HF or isolated hypotension, illustrating the potential application of a targeted proteomic approach to identify novel candidates that may support the diagnosis of CS.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Eur Heart J Acute Cardiovasc Care Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Eur Heart J Acute Cardiovasc Care Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos